Medicines Discovery Catapult

#Cancer research #Medicines Discovery Catapult #Nuclear medicine #Radiopharmaceuticals #UK

Is the UK set to become a radiopharma leader?

The latest episode of the DDW ‘In Conversation With’ series is available to listen to below. This week, Bruno Quinney speaks to Dr Juliana Maynard, Head of Translational Imaging at Medicines Discovery Catapult. MDC recently announced a partnership with the UK National Nuclear Lab, and Maynard’s… Read More

#Cancer Research #Featured Podcasts #Podcasts

#Biomarkers #Drug discovery #Epigenetics #Idiopathic pulmonary fibrosis #Medicines Discovery Catapult

How spatial epigenetics is unlocking new frontiers in drug discovery

Michael Eyres, Lead Scientist at the Medicines Discovery Catapult (MDC), explores how spatial epigenetics can accelerate biomarker drug discovery.   Epigenetics, once seen as a cryptic mix of marks on our DNA, is now central to our understanding of gene regulation in health and disease. Until recently, we studied epigenetics only in bulk tissues or single cells. But with emerging… Read More

#Exclusive Content

Radioactive containers
#Collaboration #Crown Bioscience #Medicines Discovery Catapult #Radiopharmaceuticals

MDC and Crown Bioscience collaborate on radiopharmaceutical innovation 

Medicines Discovery Catapult (MDC) and Crown Bioscience have announced a collaboration to deliver an integrated translational biology platform for companies developing radiopharmaceuticals.   The global collaboration between MDC and Crown Bioscience will support companies across the radiopharmaceutical pipeline, whether they are advancing radiotherapeutics, exploring new isotopes, or optimising targeting agents.  The… Read More

#Business & Investment #News

#Career #Drug development #Drug discovery #England #From the top #Golden Triangle #Interview #Medicines Discovery Catapult #Nanomedicine / nanotechnology #Northern Ireland #Scotland #UK #University of Oxford

New podcast: UK Spotlight: Innovation and discovery

This is the latest episode of the free DDW narrated podcast, titled “UK Spotlight: Innovation and discovery”, which covers three articles written for DDW Volume 24 – Issue 4, Fall 2023. They are called: “Where is the drug discovery expertise happening in the UK?”, “From the top: Dr… Read More

#News

Polling station sign
#Association of the British Pharmaceutical Industry #Drug discovery #Medicines Discovery Catapult #UK #UK government

UK 2024 election: A vote for drug discovery

By DDW Editor Reece Armstrong The upcoming general election in the UK has placed the priorities of the country into the spotlight and the drug discovery sector should in no way be forgotten. Economic uncertainty, challenging global conditions and a healthcare system facing serious pressures, means that whatever government takes the… Read More

#Exclusive Content #Opinion

Drug discovery innovation
#Drug discovery #ELRIG #Events #Medicines Discovery Catapult #Research

Keynotes announced for Research and Innovation 2024

The European Laboratory Research & Innovation Group (ELRIG) UK has announced the keynote speakers for its upcoming Research & Innovation conference: Steve Bates OBE FMedSci, CEO, BioIndustry Association (BIA) and Dr Anderson Ryan, Co-founder and Head of R&D and Drug Development, FasT BioPharma.   The event, taking place… Read More

#News

Demyelination of neuron
#ALS #Drug repurposing #LifeArc #Medicines Discovery Catapult #MND Association #Motor neurone disease #Neuroscience

New guiding principles to overcome barriers to MND drug discovery

New guidance for the motor neuron disease (MND) drug discovery community has been published to ensure that future drug discovery and development efforts have the best chance of successfully translating from the lab to the clinic. The whitepaper ‘Guiding principles for drug discovery and development in… Read More

#News #Trending News

Magnifying glass
#Career #From the top #Interview #Medicines Discovery Catapult

From the top: Dr Martin Main, Medicines Discovery Catapult

Listen to this article on the DDW Podcast: Megan Thomas speaks to Dr Martin Main, Chief Scientific Officer, Medicines Discovery Catapult. MT: What do you do, and how did you get here?  MM: I am Chief Scientific Officer (CSO) at Medicines Discovery Catapult (MDC). MDC is an independent, not-for-profit, national innovation… Read More

#Exclusive Content

Neuronal inclusions in Huntington’s disease
#Alchemab #Antibodies #Biologics / Biotechnology #Funding #Medicines Discovery Catapult #Neurodegenerative disorders #Neuroscience

£1.7M awarded to accelerate therapy for Huntington’s disease

Biotechnology company Alchemab Therapeutics has been awarded a grant of £1.7 million (US$2 million) from Innovate UK’s Biomedical Catalyst 2022 funding competition, to accelerate development of a first-in-class disease modifying therapy for Huntington’s disease.   Working in collaboration with Medicines Discovery Catapult (MDC), Alchemab is carrying out preclinical… Read More

#News

#Cellular imaging #Drug discovery #Medicines Discovery Catapult

MDC and ZEISS look to advance microscopy for early drug discovery  

A new partnership has been formed between Medicines Discovery Catapult (MDC) and technology group ZEISS to improve drug discovery using advanced microscopy solutions.  The partnership will combine MDC’s expertise in cell biology and drug discovery with ZEISS’ microscope instrumentation and image analysis capabilities. In particular, the organisations… Read More

#News